Iterum Therapeutics Showcases Innovations at Investment Conference

Iterum Therapeutics to Make a Mark at Global Investment Conference

Iterum Therapeutics plc (Nasdaq: ITRM), based in Dublin, Ireland and Chicago, is a prominent clinical-stage pharmaceutical company that specializes in the development of next-generation oral antibiotics. These innovative solutions aim to tackle infections caused by multi-drug resistant pathogens in community settings. In a recent announcement, Corey Fishman, the CEO of Iterum, shared exciting news regarding their participation in the 26th Annual H.C. Wainwright Global Investment Conference.

Event Details and Presentation Timing

The prestigious conference is set to take place from September 9 to September 11, 2024, at the elegant Lotte New York Palace Hotel. Iterum is scheduled for a presentation on September 10 at 8:30 am ET, during which they will discuss their advancements and future strategies. Additionally, management will offer one-on-one meetings for interested investors on the same day.

Access and Availability

Participation in the H.C. Wainwright conference is designated for qualified investors. For those unable to attend in person, a webcast of the presentation will be made available shortly afterward on Iterum’s website in the Events & Presentations section.

Commitment to Combatting Antibiotic Resistance

Iterum Therapeutics is committed to addressing the escalating global crisis of multi-drug resistant pathogens. The company is actively developing differentiated anti-infectives that aim to significantly improve health outcomes for individuals facing serious infections. Their flagship product, sulopenem, is a novel penem anti-infective with both oral and intravenous formulations.

Innovative Product Pipeline

Sulopenem has shown potent in vitro activity against numerous strains of gram-negative, gram-positive, and anaerobic bacteria that are resistant to existing antibiotics. Iterum is currently navigating the regulatory landscape, having submitted a New Drug Application (NDA) for oral sulopenem aimed at treating uncomplicated urinary tract infections in adult women. This application has been accepted for review by the U.S. Food and Drug Administration (FDA).

Regulatory Designations and Acknowledgments

In recognition of its potential, sulopenem has received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for seven distinct indications. These designations not only highlight the urgency of addressing antibiotic resistance but also facilitate the development and review process for drugs that demonstrate promise in treating serious infections.

Contact Information for Interested Parties

Investors or interested parties looking to connect with Iterum Therapeutics can reach out to Judy Matthews, the Chief Financial Officer, at 312-778-6073 or via email. The company encourages inquiries as it aims to engage with stakeholders and provide further information regarding its innovative work in the pharmaceutical field.

Frequently Asked Questions

What is the focus of Iterum Therapeutics?

Iterum Therapeutics primarily focuses on developing new oral antibiotics to combat multi-drug resistant infections.

When will Iterum present at the H.C. Wainwright Conference?

Iterum's presentation is scheduled for September 10, 2024, at 8:30 am ET.

What product is Iterum currently working on?

Iterum is advancing sulopenem, a novel anti-infective candidate designed to treat infections resistant to other antibiotics.

What regulatory designations has sulopenem received?

Sulopenem has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.

Who can attend the H.C. Wainwright Conference?

The conference is open to qualified investors interested in the latest advancements in the pharmaceutical industry.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.